Scantox Group Acquires Gentronix Ltd
September 9, 2024
Scantox Group, together with its majority owner Impilo, finalized the acquisition of Gentronix Ltd, a UK-based GLP-compliant genetic toxicology contract research organization (CRO). Gentronix is being integrated into Scantox Group to expand its genetic toxicology and genomic safety capabilities and to better support pre-IND enabling studies.
- Buyers
- Scantox Group, Impilo
- Targets
- Gentronix Ltd
- Industry
- Healthcare Services
- Location
- England, United Kingdom
- Transaction Type
- Buyout
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.